KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $22.2 billion.

  • Regeneron Pharmaceuticals' Non-Current Assets rose 22.53% to $22.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 billion, marking a year-over-year increase of 22.53%. This contributed to the annual value of $19.1 billion for FY2024, which is 40.42% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Non-Current Assets stood at $22.2 billion for Q3 2025, which was up 3.88% from $21.4 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Non-Current Assets registered a high of $22.2 billion during Q3 2025, and its lowest value of $7.7 billion during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $17.0 billion (2024), whereas its average is $17.0 billion.
  • Data for Regeneron Pharmaceuticals' Non-Current Assets shows a peak YoY soared of 56.05% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Non-Current Assets stood at $11.4 billion in 2021, then increased by 16.73% to $13.3 billion in 2022, then increased by 2.03% to $13.6 billion in 2023, then spiked by 40.42% to $19.1 billion in 2024, then rose by 22.53% to $22.2 billion in 2025.
  • Its Non-Current Assets was $22.2 billion in Q3 2025, compared to $21.4 billion in Q2 2025 and $20.0 billion in Q1 2025.